<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Traws Pharma Inc — News on 6ix</title>
<link>https://6ix.com/company/traws-pharma-inc</link>
<description>Latest news and press releases for Traws Pharma Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/traws-pharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cc3b78dffbe2df11d807.webp</url>
<title>Traws Pharma Inc</title>
<link>https://6ix.com/company/traws-pharma-inc</link>
</image>
<item>
<title>Traws Pharma Announces Up to $60 Million Private Placement Financing</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-announces-up-to-dollar60-million-private-placement-financing</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-announces-up-to-dollar60-million-private-placement-financing</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Financing led by Sirenia Capital Management LP advances Traws Pharma's influenza program through a human challenge trial for tivoxavir marboxil in the United</description>
</item>
<item>
<title>Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-completes-analysis-of-ratutrelvir-clinical-study-in-paxlovidr-eligible-and-ineligible-covid-19-patients-and-provides-updates-for-additional-indication-for-tivoxavir-marboxil-as-a-prophylactic-treatment-for-seasonal-influenza</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-completes-analysis-of-ratutrelvir-clinical-study-in-paxlovidr-eligible-and-ineligible-covid-19-patients-and-provides-updates-for-additional-indication-for-tivoxavir-marboxil-as-a-prophylactic-treatment-for-seasonal-influenza</guid>
<pubDate>Thu, 19 Feb 2026 12:30:00 GMT</pubDate>
<description>Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options Pre-clinical analysis of tivoxavir marboxil tablets demonstrated significantly increased exposure compared to a prototype formulation with predicted 28-day protection in</description>
</item>
<item>
<title>Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-completes-enrollment-ratutrelvir-133000498</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-completes-enrollment-ratutrelvir-133000498</guid>
<pubDate>Mon, 26 Jan 2026 13:30:00 GMT</pubDate>
<description>Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options Compressed tablets of tivoxavir marboxil predicted to provide 28-day protection from influenza against wide range of seasonal and pandemic-potential variants Human influenza p</description>
</item>
<item>
<title>Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-files-tivoxavir-marboxil-120000110</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-files-tivoxavir-marboxil-120000110</guid>
<pubDate>Tue, 13 Jan 2026 12:00:00 GMT</pubDate>
<description>IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile Updated clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds and faster time to sustained symptom resolution Ratutrelvir’s safety and efficacy advantage recapitulated in PAXLOVID®-ineligible patients, representing a signif</description>
</item>
<item>
<title>Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-positive-interim-110000478</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-positive-interim-110000478</guid>
<pubDate>Wed, 17 Dec 2025 11:00:00 GMT</pubDate>
<description>Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients, representing a significant population with few effective treatment options Final data analysis to be reported in January 2026 NEWTOWN, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical th</description>
</item>
<item>
<title>Traws Pharma Reports Third Quarter 2025 Results and Business Highlights</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-third-quarter-120000934</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-third-quarter-120000934</guid>
<pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
<description>Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threat</description>
</item>
<item>
<title>ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials</title>
<link>https://6ix.com/company/traws-pharma-inc/news/chemdiv-extends-cmc-services-collaboration-for-ratutrelvir-a-potential-best-in-class-covid-19-therapeutic-advancing-in-phase-2-clinical-trials</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/chemdiv-extends-cmc-services-collaboration-for-ratutrelvir-a-potential-best-in-class-covid-19-therapeutic-advancing-in-phase-2-clinical-trials</guid>
<pubDate>Thu, 30 Oct 2025 16:00:00 GMT</pubDate>
<description>ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, a promising oral antiviral treatment for COVID-19. The announcement follows recent progress by Traws Pharma, Inc. (NASDAQ: TRAW), which dosed the first patient in Phase 2 studies of ratutrelvir in October 2025, with top-line data expected by year-end 2025.</description>
</item>
<item>
<title>Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.</title>
<link>https://6ix.com/company/traws-pharma-inc/news/dover-delaware-expert-systems-inc-a-leading-life-sciences-accelerator-supports-traws-pharma-phase-2-clinical-studies-of-ratutrelvir-a-novel-ritonavir-free-antiviral-for-covid-19</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/dover-delaware-expert-systems-inc-a-leading-life-sciences-accelerator-supports-traws-pharma-phase-2-clinical-studies-of-ratutrelvir-a-novel-ritonavir-free-antiviral-for-covid-19</guid>
<pubDate>Wed, 22 Oct 2025 22:40:00 GMT</pubDate>
<description>Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a next-generation oral antiviral designed to treat newly diagnosed COVID-19 patients.</description>
</item>
<item>
<title>Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-doses-first-patient-110000213</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-doses-first-patient-110000213</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single-arm trial assessing safety and efficacy in PAXLOVID®-ineligible subjects, who represent a significant, vulnerable population with few available treatment options Top-line data from both trials expected by year-end 2025 NEWTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc</description>
</item>
<item>
<title>Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-adds-john-leaman-110000958</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-adds-john-leaman-110000958</guid>
<pubDate>Mon, 06 Oct 2025 11:00:00 GMT</pubDate>
<description>NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws’ Board of Directors (the “Board”) has eliminated the interim notation of its</description>
</item>
<item>
<title>Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-receives-approval-proceed-110000702</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-receives-approval-proceed-110000702</guid>
<pubDate>Mon, 18 Aug 2025 11:00:00 GMT</pubDate>
<description>Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety and efficacy in PAXLOVID®-ineligible subjects, who represent a significant vulnerable population with few available treatment options Top-line data from both trials expected by year-end 2025 NEWTOWN, Pa., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NA</description>
</item>
<item>
<title>Traws Pharma Reports Second Quarter 2025 Results and Business Highlights</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-second-quarter-110000951</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-second-quarter-110000951</guid>
<pubDate>Thu, 14 Aug 2025 11:00:00 GMT</pubDate>
<description>Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID, reflects the ongoing infection risk and greater need, with waning vaccine utilization A submitted HREC study will enable initiation of Phase 2 studies of ratutrelvir in newly diagnosed COVID patients, with</description>
</item>
<item>
<title>Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-report-second-quarter-110000922</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-report-second-quarter-110000922</guid>
<pubDate>Fri, 08 Aug 2025 11:00:00 GMT</pubDate>
<description>NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Web</description>
</item>
<item>
<title>Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-advances-antiviral-pipeline-103000522</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-advances-antiviral-pipeline-103000522</guid>
<pubDate>Mon, 30 Jun 2025 10:30:00 GMT</pubDate>
<description>Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID NEWTOWN, Pa., June 30, 2025 (GLOBE N</description>
</item>
<item>
<title>Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-announces-publication-compelling-110000974</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-announces-publication-compelling-110000974</guid>
<pubDate>Tue, 03 Jun 2025 11:00:00 GMT</pubDate>
<description>NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners are being actively sought, in patients with RDEB SCC. The pa</description>
</item>
<item>
<title>Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-announces-receipt-fda-120000497</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-announces-receipt-fda-120000497</guid>
<pubDate>Tue, 27 May 2025 12:00:00 GMT</pubDate>
<description>NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration (FDA, the Agency). The FDA provided feedback on developm</description>
</item>
<item>
<title>Traws Pharma Reports First Quarter 2025 Results and Business Highlights</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-first-quarter-110000073</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-first-quarter-110000073</guid>
<pubDate>Thu, 15 May 2025 11:00:00 GMT</pubDate>
<description>FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule” Additional briefing document in support of a meeting to align on ratutrelvir for COVID - including Long COVID - to be submitted to regulatory authorities in Q2 2025 Cash runway to support planned operations into Q1 2026 NEWTOWN, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc</description>
</item>
<item>
<title>Traws Pharma Reports Full Year 2024 Results and Business Highlights</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-full-2024-130000481</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-reports-full-2024-130000481</guid>
<pubDate>Mon, 31 Mar 2025 13:00:00 GMT</pubDate>
<description>Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the “Animal Rule” Cash Runway to support planned operations into Q1 2026 Investor Update call today, March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws</description>
</item>
<item>
<title>Traws Pharma Announces Management Updates</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-announces-management-updates-203000831</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-announces-management-updates-203000831</guid>
<pubDate>Fri, 28 Mar 2025 20:30:00 GMT</pubDate>
<description>Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer</description>
</item>
<item>
<title>Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET</title>
<link>https://6ix.com/company/traws-pharma-inc/news/traws-pharma-host-investor-event-113000528</link>
<guid isPermaLink="true">https://6ix.com/company/traws-pharma-inc/news/traws-pharma-host-investor-event-113000528</guid>
<pubDate>Wed, 26 Mar 2025 11:30:00 GMT</pubDate>
<description>Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird FluRatutrelvir, a main protease inhibitor, to be used without ritonavir, for COVID-19 NEWTON, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human healt</description>
</item>
</channel>
</rss>